Economy- and Social-Based Strategies for Anticoagulation of Patients with Atrial Fibrillation

• Published in: Arquivos brasileiros de cardiologia Vol. 118; no. 1; p. 88
• Main Authors: Guerrero, Andressa Zulmira Avila, Coutinho, Enia Lucia, Ferraz, Marcos Bosi, Cirenza, Claudio, Santos, Marcelo Cincotto Esteves Dos, Ferraro, José Roberto, Paola, Angelo Amato Vincenzo de
• Format: Journal Article
• Language: English
• Published: Brazil 01-01-2022
• Subjects: Administration, Oral; Anticoagulants; Atrial Fibrillation - complications; COVID-19; Humans; Quality of Life; Retrospective Studies; SARS-CoV-2; Stroke - drug therapy; Stroke - prevention & control
• ISSN: 1678-4170; 1678-4170
• DOI: 10.36660/abc.20200921

Atrial fibrillation is a public health problem associated with a fivefold increased risk of stroke or death. Analyzing costs is important when introducing new therapies and must be reconsidered in special situations, such as the novel coronavirus pandemic of 2020.
This study aimed to evaluate the costs related to anticoagulant therapy in a one-year period, and the quality of life of atrial fibrillation patients treated in a public university hospital.
Patient costs were those related to the anticoagulation and calculated by the average monthly costs of warfarin or direct oral anticoagulants (DOACs). Patient non-medical costs (eg., food and transportation) were calculated from data obtained by questionnaires. The Brazilian SF-6D was used to measure the quality of life. P-values < 0.05 were considered statistically significant.
The study population consisted of 90 patients, 45 in each arm (warfarin vs direct oral anticoagulants). Costs were 20% higher in the DOAC group ($55,532.62 vs $46,385.88), and mainly related to drug price ($23,497.16 vs $1,903.27). Hospital costs were higher in the warfarin group ($31,088.41 vs $24,604.74) and related to outpatient visits. Additionally, non-medical costs were almost twice higher in the warfarin group ($13,394.20 vs $7,430.72). Equivalence of price between the two drugs could be achieved by a 39% reduction in the price of DOACs. There were no significant group differences regarding quality of life.
Total costs were higher in the group of patients taking DOACs than those taking warfarin. However, a nearly 40% reduction in the price of DOACs could make it feasible to incorporate these drugs into the Brazilian public health system.